Skip to main content

CTOS 2023 Main banner

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Frederick Klauschen, MD

Institute of Pathology, Ludwig-Maximilians-University (LMU) Munich, Germany, Germany

Poster(s):

(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)